M/s Panacea Biotech, New Delhi

 
 

Recipient of “BioSpectrum Product of the year Award, 2011”
And “India Nanotech Innovation Award, 2011”.

M/s Panacea Biotec is the first Indian company to have indigenously developed and commercialized an innovative product “PacliALL”, a nano-technology based formulation of albumin-bound Paclitaxel particles for effective treatment of breast cancer. PacliALL uses one of the world’s most advanced particle size optimization technology to reduce serious adverse effects, including severe anaphylaxis and sensory neuropathy associated with conventional Paclitaxel formulations.

The Company has offered PacliALL at 50% lower cost to patients in India. The Company has set up a manufacturing facility at Baddi with an annual capacity of 1.2 million vials, investing Rs.55 Crores out of which TDB has provided Rs.5 Cr.as term loan at a concessional rate of interest.

©2017  Technology Development Board All Rights Reserved. Website maintained by Elegant MicroWeb.